Milan, 4 August 2020 – LIFTT, the investment operating company founded by Fondazione Compagnia Di San Paolo and Politecnico di Torino, and Bioengineering Laboratories S.r.l. (“BEL”), a medical device company controlled by the Delta Med group and by the founder Francesco Greco, announce a strategic-financial partnership in the BioMed sector.
Read the news: LIFTT focuses on Dialybrid
Bioengineering Laboratories was awarded the illustrious (and highly competitive!) SME Instrument Phase 1 grant, appointed by the European Commission to SMEs with a strong growth potential and the ambition to become world-market leaders. The grant will support BEL in undertaking the DIALYBRID project, aimed at revolutionizing the world of hemodialysis with a novel, hybrid vascular access made of Silkothane®.
Bioengineering Laboratories gladly accepts the invitation to join the 1st Italian Chapter of the Vascular Access Society, held in Turin together with the 7th national congress of the “Vascular Access Design Group”. Many thanks to the organizers, Dr. Giacomo Forneris and Dr. Daniele Savio, for giving BEL the possibility to illustrate the breakthrough potential of Silkothane® in the world of hemodialysis.
Bioengineering Laboratories was awarded the second prize at the Business Plan Competition of the 5th World Congress of TERMIS – Tissue Engineering and Regenerative Medicine International Society (Kyoto, Japan, https://www.termis.org/wc2018). BEL’s business plan and presentation pitch focused on the DIALYBRID project, aimed at revolutionizing the world of hemodialysis with a novel, hybrid vascular access made of Silkothane®.
Bioengineering Laboratories joined the “40th International Conference of the IEEE Engineering in Medicine and Biology Society” (Honolulu, Hawaii), to present, in collaboration with Politecnico di Milano, the results obtained by the biological tissues analysis through modulus and phase of impedance. The developed device is composed by a needle-prove and an ad-hoc impedance meter for the analysis and discrimination of living tissues.
Bioengineering Laboratories was awarded the prestigious “Seal of excellence” of the European Commission for its project DIALYBRID, aimed at revolutionizing the world of hemodialysis with a novel, hybrid vascular access made of Silkothane®.
The project was submitted under the Horizon 2020’s “SME Instrument – Phase 1” call of May 3rd, 2018, and it was scored as a high-quality project proposal in a highly competitive evaluation process.
Bioengineering Laboratories joined the 39th International Conference of the IEEE Engineering in Medicine and Biology Society (Jeju Island, Korea), to present, in collaboration with Politecnico di Milano, the development of a new impedance device for the tissues electrical characterization.
The new detection device for an in-depth tissue examination has been developed with the specific purpose to obtain an 8-electrodes-needle-probe to be used for ex-vivo tissue measurements and able to provide useful raw data to successively reconstruct an impeditivity map, at a given frequency, based on the conductivity contrast among the different areas.
https://embc.embs.org/2017/
Bioengineering Laboratories joined the 10th Congress of the Vascular Access Society in Ljubljana (Slovenia), to present the breakthrough development of a novel, revolutionary vascular access made of silk fibroin and SilkothaneTM.
BEL’S innovative, patent pending technology is based on the electrospinning of silk fibroin and SilkothaneTM, to create a semi-degradable vascular access that encompasses the remodeling capabilities of native fistulae as well as the controlled mechanical properties of synthetic grafts.
http://www.vas2017.org/
BEL has been one of the first companies in Europe to obtain the ISO13485:2016 certification.
Design and development, manufacture and marketing of inactive medical devices for anesthesia, emergency and intensive care, for urodynamics, gastroenterology and urology, and inactive medical devices for injection, infusion, dialysis and Extracorporeal blood circulation, cardiac surgery and vascular access. Production of hypodermic needles for third parties.
